Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1991 Apr;63(4):630–633. doi: 10.1038/bjc.1991.144

The effect of carboplatin on renal function in patients with metastatic germ cell tumours.

M D Mason 1, J Nicholls 1, A Horwich 1
PMCID: PMC1972356  PMID: 1850612

Abstract

Renal function was determined before and at varying times after chemotherapy in 62 patients with metastatic germ cell tumours treated with carboplatin. Eighteen patients were excluded because of urinary tract obstruction, leaving 44 evaluable patients treated with carboplatin either as a single agent (13 patients) or in combination with other agents (31 patients). No significant differences were observed in mean 51Cr-labelled Ethylenediamine tetraacetic acid (EDTA) clearances before and after carboplatin in either the group as a whole (P = 0.58), or when assessment at 1 month or less (P = 0.4), 3 months or less (P = 0.91), or later than 3 months (P = 0.38) were analysed. Carboplatin does not have significant renal toxicity when used at conventional dosage in patients with germ cell tumours.

Full text

PDF
630

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barton C., Duchesne G., Williams M., Fisher C., Horwich A. The impact of hydronephrosis on renal function in patients treated with cisplatin-based chemotherapy for metastatic nonseminomatous germ cell tumors. Cancer. 1988 Oct 1;62(7):1439–1443. doi: 10.1002/1097-0142(19881001)62:7<1439::aid-cncr2820620732>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  2. Bregman C. L., Williams P. D. Comparative nephrotoxicity of carboplatin and cisplatin in combination with tobramycin. Cancer Chemother Pharmacol. 1986;18(2):117–123. doi: 10.1007/BF00262279. [DOI] [PubMed] [Google Scholar]
  3. Calvert A. H., Harland S. J., Newell D. R., Siddik Z. H., Harrap K. R. Phase I studies with carboplatin at the Royal Marsden Hospital. Cancer Treat Rev. 1985 Sep;12 (Suppl A):51–57. doi: 10.1016/0305-7372(85)90018-0. [DOI] [PubMed] [Google Scholar]
  4. Chantler C., Garnett E. S., Parsons V., Veall N. Glomerular filtration rate measurement in man by the single injection methods using 51Cr-EDTA. Clin Sci. 1969 Aug;37(1):169–180. [PubMed] [Google Scholar]
  5. Dentino M., Luft F. C., Yum M. N., Williams S. D., Einhorn L. H. Long term effect of cis-diamminedichloride platinum (CDDP) on renal function and structure in man. Cancer. 1978 Apr;41(4):1274–1281. doi: 10.1002/1097-0142(197804)41:4<1274::aid-cncr2820410410>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  6. Egorin M. J., Van Echo D. A., Tipping S. J., Olman E. A., Whitacre M. Y., Thompson B. W., Aisner J. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. Cancer Res. 1984 Nov;44(11):5432–5438. [PubMed] [Google Scholar]
  7. Gore M. E., Calvert A. H., Smith L. E. High dose carboplatin in the treatment of lung cancer and mesothelioma: a phase I dose escalation study. Eur J Cancer Clin Oncol. 1987 Sep;23(9):1391–1397. doi: 10.1016/0277-5379(87)90125-8. [DOI] [PubMed] [Google Scholar]
  8. Groth S., Nielsen H., Sørensen J. B., Christensen A. B., Pedersen A. G., Rørth M. Acute and long-term nephrotoxicity of cis-platinum in man. Cancer Chemother Pharmacol. 1986;17(2):191–196. doi: 10.1007/BF00306754. [DOI] [PubMed] [Google Scholar]
  9. Hamilton C. R., Bliss J. M., Horwich A. The late effects of cis-platinum on renal function. Eur J Cancer Clin Oncol. 1989 Feb;25(2):185–189. doi: 10.1016/0277-5379(89)90006-0. [DOI] [PubMed] [Google Scholar]
  10. Hansen S. W., Groth S., Daugaard G., Rossing N., Rørth M. Long-term effects on renal function and blood pressure of treatment with cisplatin, vinblastine, and bleomycin in patients with germ cell cancer. J Clin Oncol. 1988 Nov;6(11):1728–1731. doi: 10.1200/JCO.1988.6.11.1728. [DOI] [PubMed] [Google Scholar]
  11. Horwich A., Dearnaley D. P., Duchesne G. M., Williams M., Brada M., Peckham M. J. Simple nontoxic treatment of advanced metastatic seminoma with carboplatin. J Clin Oncol. 1989 Aug;7(8):1150–1156. doi: 10.1200/JCO.1989.7.8.1150. [DOI] [PubMed] [Google Scholar]
  12. Meijer S., Sleijfer D. T., Mulder N. H., Sluiter W. J., Marrink J., Koops H. S., Brouwers T. M., Oldhoff J., van der Hem G. K., Mandema E. Some effects of combination chemotherapy with cis-platinum on renal function in patients with nonseminomatous testicular carcinoma. Cancer. 1983 Jun 1;51(11):2035–2040. doi: 10.1002/1097-0142(19830601)51:11<2035::aid-cncr2820511113>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  13. Shea T. C., Flaherty M., Elias A., Eder J. P., Antman K., Begg C., Schnipper L., Frei E., 3rd, Henner W. D. A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J Clin Oncol. 1989 May;7(5):651–661. doi: 10.1200/JCO.1989.7.5.651. [DOI] [PubMed] [Google Scholar]
  14. Sleijfer D. T., Smit E. F., Meijer S., Mulder N. H., Postmus P. E. Acute and cumulative effects of carboplatin on renal function. Br J Cancer. 1989 Jul;60(1):116–120. doi: 10.1038/bjc.1989.233. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES